InnoCare Signs Discovery Deal With Lilly Worth Up to $3.35 Billion for Up to Five Cancer and Autoimmune Targets
InnoCare Pharma announced on Thursday, September 24, 2026 a research collaboration and license agreement with Eli Lilly to discover medicines against up to five undisclosed targets in cancer and autoimmune disease. InnoCare can receive up to $100 million in upfront and near-term payments and up to about $3.25 billion in development and commercial milestones, plus single-digit tiered royalties on sales. InnoCare will use its own discovery platform to find and advance compounds; the announcement did not specify the type of drug.